Douglas Jermasek
Executive Vice President of Corporate StrategyMr. Douglas Jermasek, M.B.A., also known as Doug, serves as Executive Vice President of Corporate Strategy at Unicycive Therapeutics, Inc. since November 2021 and joined Unicycive Therapeutics, Inc. in 2021. He was Vice President of Marketing and Strategy at Akebia Therapeutics, Inc. He was Vice President of Marketing and Strategy at Keryx Biopharmaceuticals Inc. since July 01, 2016 until December 12, 2018. Mr. Jermasek served as the Chief Executive Officer at Deltanoid Pharmaceuticals, Inc. since February 2, 2016. Prior to joining Keryx, from 2002 to 2014, he had commercial roles of increasing responsibility within Genzyme/Sanofi's global renal business, culminating in 2012 when he was appointed to the role of Senior Vice President and General Manager of that business. Mr. Jermasek has held positions of progressive responsibility at Hybritech/Lilly, Abbott Laboratories, Agouron/Pfizer, Prometheus and served as the Head of North America at Intercept Pharmaceuticals. Mr. Jermasek has biopharmaceutical industry experience. He received an M.B.A. in Business Administration and Management from the Marriott School of Management in the year 1987 to 1989 and earned a B.S. in biological science from Brigham Young University.
Positions
- Company NameUnicycive Therapeutics, Inc.Stock CodeUNCYPositionExecutive Vice President of Corporate StrategyColleagues
- SKShalabh K. GuptaFounder, Chairman, CEO & President
- PGPramod GuptaExecutive Vice President of Pharmaceutical and Business Operations
- JWJohn W. TownsendChief Financial Officer
- SLSandeep LaumasIndependent Director
- SKSaraswati Kenkare-MitraIndependent Director
- MSMeredith S. ManningIndependent Director
- RLRavindra L. MehtaMember of Scientific Advisory Board
